Supplementary Material for: Host MICA Polymorphism as a Potential Predictive Marker in Response to Chemotherapy for Colorectal Liver Metastases

<b><i>Background:</i></b> Understanding the genetic background of a tumor is important to better stratify patient prognosis and select optimal treatment. For colorectal liver metastases (CLM), however, clinically available biomarkers remain limited. <b><i>Methods:</i></b> After a comprehensive sequencing of 578 cancer-related genes in 10 patients exhibiting very good/poor responses to chemotherapy, the A5.1 variant of the <i>MICA</i> gene was selected as a potential biomarker for CLM. The clinical relevance of <i>MICA</i> A5.1 was then investigated in 58 patients who underwent CLM resection after chemotherapy. <b><i>Results:</i></b> The A5.1 variant was observed in 16 (27.6%) patients examined using direct DNA sequencing, and a very high concordance rate (56/58, 96.6%) for the <i>MICA</i> variant was confirmed between tumor tissues and normal liver parenchyma. A multivariate analysis of 38 patients with no history of treatment with anti-EGFR antibodies confirmed that <i>MICA</i> A5.1 was significantly correlated with an optimal CT morphologic response (OR 11.67; 95% CI 2.08–65.60; <i>p</i> = 0.005) and tended to be correlated with a tumor viability of < 20% after chemotherapy (OR 5.91; 95% CI 0.97–36.02; <i>p</i> = 0.054). <i>MICA</i> A5.1 was also associated with a decreased risk of progression after CLM resection. <b><i>Conclusion:</i></b> The <i>MICA</i> A5.1 polymorphism was associated with a better CT morphologic response to chemotherapy and a reduced risk of relapse after CLM resection. Given the high concordance rate in <i>MICA</i> variants between normal liver tissue and CLM, the genetic background of the host could be a new biomarker for CLM.